The group's principal activities include drug discovery, development and predictive toxicology through the use of embryonic stem cells (ES cells) technologies and associated bioinformatics systems. The products of the group include small molecule drugs and protein therapeutics for diabetes, Parkinson's disease, brain disorders and other neurological disorders. The group operates from California, United States.
